Monrovia's Xencor Reports Smaller Loss Than For Same Time Last Year

Monrovia corporation, Xencor, reported a net loss for the first quarter ended March 31 of $2.5 million, or $(0.04) per share, compared to a net loss of $8.1 million, or $(0.14) per share for the same period in 2020. Xencor is a clinical-stage biopharmaceutical company developing cancer and autoimmune disease treatments.  Details: https://is.gd/OpTHZN

- Brad Haugaard